Fraunhofer ITEM

From November 12 to 13, 2024, the Leipzig Immune Oncology (LION) Conference 2024 will take place in Leipzig. The LION Conference will bring together clinicians, scientists and industry to discuss latest developments and highlights on special issues of immune oncology. The LION Conference 2024 is hosted by Fraunhofer IZI and the University Hospital Leipzig. Scientists from Fraunhofer ITEM will be presenting their work: 🗣️Our lecture: »CD109 as a target for lung cancer and tumor-associated macrophages«, given by Tine Haesen 📅 Date: Tuesday, November 12, 2024 🕔 Time: 5:00 – 7:00 p.m., Session III 🪧 Our posters: ▶️"Anti-CD123-CAR-NK-92 cells reduce monocyte population in human blood – a potential risk of infection susceptibility for the patient?" by Susann Dehmel ▶️"Modulation of CD8 T cell responses at the human ex vivo tumor front" by Tonia Bargmann ▶️"Interleukin-2 induces type 2 and 17 skin inflammation in a CD25-dependent manner" and ▶️"Interleukin-2 dynamically reduces interleukin-2 receptor β expression and function especially in T cells" both by Charline Sommer For more information please refer to the conference website: https://lnkd.in/eY_Zm45K #immunotherapy #LIONconf2024 #oncology #CellTherapy

🎉Liebe PD. Dr. Katherina Sewald - Herzlichen Glückwunsch zur Habilitation🎉 Das gesamte Team des Fraunhofer ITEM gratuliert dir auch auf diesem Wege von Herzen zu diesem großartigen Meilenstein #soproud 💪! In deiner beeindruckenden Antrittsvorlesung hast du uns gestern mit Einblicken in das Thema »Asthma verstehen: Atmen wollen, aber nicht können – Neue Wege der Pharmakologie mit humanem Lungengewebe« begeistert 🌬️🫁. Deine herausragenden Forschungsarbeiten eröffnen neue Perspektiven in der Behandlung von Asthma und weiteren Atemwegserkrankungen und tragen entscheidend zur Weiterentwicklung innovativer Therapieansätze bei, wie beispielsweise ganz aktuell im EU-Projekt imSAVAR. Dein Engagement und deine Expertise bereichern nicht nur unser Institut, sondern auch die wissenschaftliche Gemeinschaft. Als #Fraunhofer-Mitarbeiterin an der Medizinische Hochschule Hannover (MHH) zu habilitieren ist ein weiterer Beweis für die enge und erfolgreiche Zusammenarbeit zwischen Forschung und Klinik hier in Hannover 🏥🔬. Wir sind sehr stolz, dich in unserem Team zu haben und dankbar für dein Engagement und deine wichtige Rolle als Mentorin für unsere Nachwuchswissenschaftlerinnen und -wissenschaftler an unserem Institut. Wir freuen uns auf viele weitere spannende Projekte und gemeinsame Erfolge! #Habilitation #Translationsforschung #Asthmaforschung #Pharmakologie #PCLS #exvivo

Great article, we are pleased to contribute to this exciting project 🚀! The clinical trial with healthy volunteers and IPF patients has started at Fraunhofer ITEM with Prof. Jens Hohlfeld, who has discussed the ongoing testing of a new substance aimed at promoting lung tissue regeneration in the article, as principal investigator.

📢 Call for Abstract Submission! We are excited to co-host a session titled "Advances in Exposure Modelling Towards a Safe and Sustainable Tomorrow for Both Humans and the Environment" at the 35th Annual SETAC Europe Meeting, taking place from May 11 to 15, 2025. 🌟 Session Overview 🌟 #ExposureAssessment of chemicals and materials is a key component of risk assessment and management for human health and environmental protection. Models play a crucial role in assessing the release, transport, fate, and exposure of chemicals, enabling concentration estimates across air, soil, water, sediment, and biota - including human exposure. While these models are well-established in both research and regulatory contexts, the increasing diversity of chemicals under review and the drive for greater ecological realism are pushing traditional modelling boundaries. The International Society of Exposure Science is exploring a holistic exposure modelling strategy, opening new avenues for integrating human and environmental exposure data. Modelling complements monitoring data by offering comparative assessments of chemicals at early stages in the product life cycle, aiding in the early identification of exposure risks, and examining drivers of chemical fate and exposure across various environmental and socioeconomic scenarios. This makes modelling a vital tool in safe-and-sustainable-by-design (#SSbD) frameworks. Our session will spotlight cutting-edge advances in exposure modelling, with a focus on how innovative tools and frameworks are addressing scientific and regulatory challenges in risk assessment and management, contributing to safer, more sustainable chemical use throughout product life cycles. 🔹 Session Chairs: Stefan Hahn, Fraunhofer ITEM, Antonia Praetorius, Universiteit van Amsterdam, Joris Quik, RIVM National Institute for Public Health and the Environment, and Stephen Lofts, UK Centre for Ecology & Hydrology (UKCEH) 🔹 Abstract Submission Deadline: November 20, 2024 👉Don't miss the chance to share your research with a global audience and join us in advancing the field! Submit your abstract by November 20. 🌐For more details and to submit your abstract, visit the SETAC Europe conference page: https://lnkd.in/gSkwQYWw #SETAC2025 #EnvironmentalScience #ExposureModelling #Sustainability 

📢We have already started with the preparations for our annual conference "Models of Lung Disease"! Are you interested in diving deep into topics such as ▶️ human immune competent models of lung disease ▶️ RNA based technologies in research and drug development ▶️ new anti-infective strategies ▶️ understanding and fighting fibrosis in the field of respiratory diseases next year? Then please save the date for "Models of Lung Disease 2025": 📅June 19-20, 2025 We are already looking forward to the conference and the scientific exchange with you!🙂 More information will follow... We will keep you updated!👈 #ModelsofLungDisease2025 #lungresearch #lung #diseasemodels

Excited to connect at #BioEurope2024! Let’s explore solutions tailored to your research needs: 🔬 #InhalationToxicology: We offer customized aerosolization and testing solutions for drug candidates, including small molecules, recombinant proteins, cell and gene therapies, and bacteriophages. 🦠 #InfectionResearch & #Immunology: From patented in-vitro to complex ex-vivo and in-vivo models, our services support disease-relevant, dose-dependent, and reproducible studies. We are happy to test the efficacy of your lead compound. 🫁 #FibrosisResearch: We provide ex-vivo models for preclinical studies on organ fibrosis (lung, liver, intestine) with access to human fibrotic tissue (end-stage) and early-stage models for effective efficacy testing. 🎯 #PersonalizedTumorTherapy: Supporting your journey through Technology Development, Preclinical Application, and Clinical Translation. 💊 #GMPManufacturingOfBiopharmaceuticals: Comprehensive services to support the lifecycle of your drug product up to Phase I and II clinical trials for industry partners. 🔎 #PEDRA (Platform for Ex-Vivo Drug Response Assays): PEDRA includes diverse ex-vivo assays, allowing robust drug safety and efficacy assessments across a broad spectrum of anticancer treatments. Looking forward to meaningful discussions on advancing these fields: Dorothee Winterberg, Franziska Dahlmann, Christina Hesse, Sebastian Konzok, Christopher Jakobs, PhD, Lukas Wöhrl, Christian Heine!

👉One month ago, the CIMD Symposium on RNA-based therapeutics took place at our institute. On this occasion, Prof. Christian Bär, symposium chair and leader of the platform “RNA Therapeutics” of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD emphasized Germany as a hotspot for research and clinical translation of microRNAs in his overview lecture. Shortly afterwards, it was announced that the Nobel Prize for Physiology or Medicine is awarded in the field of microRNA research. 🔎Micro ribonucleic acids, short microRNAs, have great potential for the research on various diseases and the development of therapies, as they have significant effects on gene regulation and play a key role in many diseases. They allow for a better understanding of biological processes and the personalization of treatments or can be used as biomarkers for diseases. In the CIMD platform “RNA Therapeutics”, we are working together with our partners to map a potential pathway that an RNA-based drug will follow from discovery to clinical use. In the context of our symposium on September 30, we could see how challenging, but also exciting this is. ▶️ Sneak peek🙂: The symposium will definitely be repeated. 📢We keep you posted. #RNA #RNAresearch #RNAtherapeutics #microRNA

Do we meet at #BioEurope2024 in Stockholm next week 🤝? Feel free to reach out to us in advance on the following topics: ▶️Inhalation Toxicology ▶️Infection Research and Immunology ▶️Fibrosis Research ▶️Personalized Tumor Therapy ▶️GMP manufacturing of biopharmaceuticals Dorothee Winterberg, Franziska Dahlmann Christina Hesse, Sebastian Konzok, Lukas Wöhrl Christopher Jakobs, PhD and Christian Heine look forward to meeting you at our joint Fraunhofer Gesundheit booth #43A! 🌐Please visit our website for more details: https://lnkd.in/eT6gT5xF

🔬💼 Dr. Gustav Bruer has been head of the department of Inhalation Toxicology at Fraunhofer ITEM since February 2021. What he likes most about his work is its variety, as no two days are the same and every project yields new challenges. His department is financially independent, which means that Gustav cannot exclusively consider science but needs to pay attention to economics as well. He particularly enjoys the great collaboration of his team as well as the exchange with customers and project partners around the world. 🌍 👨🎓 Gustav was particularly influenced by his doctoral supervisor, Professor Kietzmann, who emphasized the importance of finding a truly exciting topic to work on. This passion and dedication enables Gustav to achieve great things without his daily work feeling like a burden. 🏆 Gustav is especially proud of the current nanoparticle project, as this project demonstrates how small details in research can lead to big changes, right up to the global application or elimination of substances. 📚 Besides his job’s main tasks, Gustav values the advice and support of mentors and colleagues he gets from mutual exchange. This exchange has not only fostered his professional development but has also led to great, non-work-related friendships. 🚗 If he’s not working, Gustav loves to spend time with his car. The sound of the engines, the whistling of the turbochargers and the roar of the exhaust make him feel alive and help him kick back. For him, a successful day consists of a balance between productivity and relaxation, according to the motto ‘Business before pleasure’. 🔗 Read Gustav’s full portrait on our careers page: https://lnkd.in/eTdfNa4D #yourITEMjob #inhalationtoxicity

#newpublication: Exciting News from our “Personalized Tumor Therapy” department! We are happy to announce that our manuscript titled "Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients" has just been published online! 🌐👉https://lnkd.in/ew2zg7YE In this study, we explored the potential of cellular liquid biopsy (cLB) as a precision oncology tool, specifically for patients with rare salivary gland cancers. Our findings reveal the significant role of cLB and tumoroids as a preclinical model in disease monitoring and personalized treatment strategies. A special thanks to our dedicated team from Fraunhofer ITEM and the Universitätsklinikum Regensburg: Christian Werno, Natasa Stojanovic Guzvic, Florian Lüke, Prof. Dr. med. Tobias Pukrop, Kamran Honarnejad, Christoph Klein, Bernhard Polzer, Steffi Treitschke, Andrea Coluccio, PhD, Martin Hoffmann, Giancarlo Feliciello, Dr. Adithi Varadarajan, Catherine Botteron. We would also like to extend our gratitude to the patients and their families for their invaluable participation, as well as to the physicians for their great cooperation 🙏 . If you are interested in #translationalresearch on #LiquidBiopsy and ex vivo drug screening, please also check our webpage: 🌐👉https://lnkd.in/gthp_TZF   #oncology #tumorresearch #precisionmedicine #tumoroids